Second-line or subsequent systemic therapy for recurrent or progressive non-small cell lung cancer: A systematic review and practice guideline

Journal of Thoracic Oncology

Volumn 1, Issue 9, 2006, Pages 1042-1058

  Noble, J ^a   Ellis, P M ^b   Mackay, J A ^b   Evans, W K ^b  

^a SUDBURY REGIONAL HOSPITAL   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

Non small cell lung cancer; Recurrence; Retreatment; Systematic review

Indexed keywords

4 N ACETYLDINALINE; BORTEZOMIB; CELECOXIB; CISPLATIN; CYANOCOBALAMIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EPOTHILONE DERIVATIVE; ERLOTINIB; FOLIC ACID; GEFITINIB; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; HISTONE DEACETYLASE INHIBITOR; IFOSFAMIDE; IRINOTECAN; IXABEPILONE; NAVELBINE; PEMETREXED; PIVALOYLOXYMETHYL BUTYRATE; PLACEBO; TOPOTECAN; ANTINEOPLASTIC AGENT; TAXOID;

ALOPECIA; ANEMIA; ANOREXIA; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DEATH; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; INFECTION; LEUKOPENIA; LUNG DISEASE; LUNG NON SMALL CELL CANCER; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NAUSEA; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH; RECURRENT DISEASE; REVIEW; SEPSIS; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SYMPTOM; SYSTEMIC THERAPY; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; VITAMIN SUPPLEMENTATION; CANADA; CANCER STAGING; DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; FOLLOW UP; INTRAVENOUS DRUG ADMINISTRATION; LUNG TUMOR; MALE; MAXIMUM TOLERATED DOSE; META ANALYSIS; MORTALITY; PALLIATIVE THERAPY; PATHOLOGY; PRACTICE GUIDELINE; RISK ASSESSMENT; SURVIVAL; TIME; TUMOR RECURRENCE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE III; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; ONTARIO; PALLIATIVE CARE; PRACTICE GUIDELINES; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; SURVIVAL ANALYSIS; TAXOIDS; TIME FACTORS;

EID: 34247871456     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/s1556-0864(15)31641-5     Document Type: Review

References (58)

1. American Cancer Society, Cancer Facts and Figures 2006. Atlanta: American Cancer Society;2006:4.
2. Travis WD, Travis LB, Devesa SS. Lung cancer. Cancer. 1995;75:191-202.
3. Thomas CJ, Williams TE, Cobos E, et al. Lung Cancer. In: Lenhard RE, Jr., Osteen RT, Gansler T, Eds. Clinical oncology. Atlanta (GA): The American Cancer Society, 2001:269-295.
4. Lilenbaum RC, Herndon JE, List MA, et al. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). J Clin Oncol. 2005;23:190-196.
5. Fossella F, Pereira JR, von Pawel, J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small cell lung cancer: the TAX 326 Study Group. J Clin Oncol. 2003;21:3016-3024.
6. Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small cell lung cancer. J Clin Oncol. 2002;20:4285-4291.
7. Gatzemeier U, von Pawel, J, Gottfried M, et al. Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2000;18:3390-3399.
8. Logan D, Laurie S, Markman BR, et al. The role of single-agent docetaxel as second-line treatment for advanced non-small-cell lung cancer. Curr Oncol. 2001;8:50-59.
9. Browman GP, Levine MN, Mohide EA, et al. The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation. J Clin Oncol. 1995;13:502-512.
10. Vale CL, Tierney JF, Stewart LA. Effects of adjusting for censoring on meta-analyses of time-to-event outcomes. Int J Epidemiol. 2002;31:107-111.
11. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000;18:2095-2103.
12. Dancey J, Shepherd FA, Gralla RJ, et al. Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trial. Lung Cancer. 2004;43:183-194.
13. Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol. 2000;18:2354-62.
14. Miller V, Fossella F, DeVore R, et al. Docetaxel (D) Benefits Lung Cancer Symptoms and Quality of Life (QoL) in a Randomized Phase III Study of Non-Small Cell Lung Cancer (NSCLC) Patients Previously Treated with Platinum-Based Therapy (Meeting abstract) [abstract]. Proc Am Soc Clin Oncol. 1999;18:491a. Abstract 1895.
15. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22:1589-1597.
16. Pujol JL, Shaharyar S, Kortsik C, et al. Post study docetaxel in non-small cell lung cancer (NSCLC) patients after discontinuation from a randomized phase III trial of pemetrexed versus docetaxel: An exploratory analysis [abstract]. J Clin Oncol ASCO Annu Meeting Proc. (Post-Meeting Edition) 2004;22 (Jul 15 Suppl 14S):A7135.
17. Ramlau R, Gervais R, Krzakowski M, et al. Oral topotecan demonstrates clinical activity in relapsed non-small cell lung cancer. Results from an open-label, phase III study (387) comparing oral topotecan to intravenous docetaxel [abstract]. J Clin Oncol. 2005;23(Suppl 16S):A7017.
18. Ramlau R, Gervais R, Krzakowski M, et al. Oral topotecan demonstrates clinical activity in relapsed non-small cell lung cancer. Results from an open-label, phase III study (387) comparing oral topotecan to intravenous docetaxel [Slide presentation online]. Available at: http://www.asco.org/ac/ 1,1003,_12-002511-00_18-0034-00_19-003868,00.asp. Accessed June 28, 2005.
19. Hainsworth JD, Burris HA, Erland JB, et al. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol. 1998;16:2164-2168.
20. Camps C, Massuti B, Jimenez AM, et al. Second-line docetaxel administrated every 3 weeks versus weekly in advanced non-small-cell lung cancer (NSCLC): a Spanish Lung Cancer Group (SLCG) phase III trial [abstract]. Proc Am Soc Clin Oncol. 2003;22:625. Abstract 2514.
21. Camps C, Massuti B, Jimenez AM, et al. Two second-line docetaxel dose-schedules in advanced non-small-cell lung cancer (NSCLC): a Spanish Lung Cancer Group (SLCG) phase III trial [ASCO slide presentation online]. Available at: http://www.asco.org/ac/1,1003,_12-002511-00_18-0023-00_19-001507,00.asp. Accessed August 11, 2004.
22. Gridelli C, Gallo C, Di Maio M, et al. A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study. Br J Cancer. 2004;91:1996-2004.
23. Schuette W, Nagel S, Blankenburg T, et al. Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel. J Clin Oncol. 2005;23:8389-8395.
24. Gervais R, Ducolone A, Breton JL, et al. Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC). Ann Oncol. 2005;16:90-96.
25. Camps C, Massutl B, Jimenez AM, et al. Quality-of-Life (QOL) assessment in two docetaxel dose-schedules as second-line treatment of advanced non small cell lung cancer (NSCLC): Spanish Lung Cancer Group (SLCG) Phase III trial. [abstract]. Lung Cancer. 2005;49(Suppl 2):S87.
26. Quoix E, Lebeau B, Depierre A, et al. Randomised, multicentre phase II study assessing two doses of docetaxel (75 or 100 mg/m2) as second-line monotherapy for non-small-cell lung cancer. Ann Oncol. 2004;15:38-44.
27. Takeda K, Negoro S, Tamura T, et al. Docetaxel (D) versus docetaxel plus gemcitabine (DG) for second-line treatment of non-small cell lung cancer (NSCLC): results of a JCOG randomized trial (JCOG0104) [abstract]. Proc Am Soc Clin Oncol. 2004;23:Abstract 7034.
28. Takeda K, Negoro S, Tamura T, et al. Docetaxel (D) versus docetaxel plus gemcitabine (DG) for second-line treatment of non-small cell lung cancer (NSCLC): results of a JCOG randomized trial (JCOG0104) [ASCO slide presentation online]. Available at: http://www.asco.org/ac/1,1003,_12-002511-00_18-0026- 00_19-009824,00.asp. Accessed August 11, 2004.
29. Pectasides D, Pectasides M, Farmakis D, et al. Comparison of docetaxel and docetaxel-irinotecan combination as second-line chemotherapy in advanced non-small-cell lung cancer: a randomized phase II trial. Ann Oncol. 2005;16:294-299.
30. Wachters FM, Groen HJ, Biesma B, et al. A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb-IV non-small-cell lung cancer who failed first-line treatment. Br J Cancer. 2005;92:15-20.
31. Keresztes RS, Socinski MA, Lilenbaum R, et al. Phase II randomized trial of irinotecan/docetaxel (ID) or irinotecan/gemcitabine (IG) with or without celecoxib (CBX) in 2nd-line treatment of non-small-cell lung cancer (NSCLC) [Slide presentation online]. Available at: http://www.asco.org/ac/1,1003,_12- 002511-00_18-0026-00_19-0010708,00.asp. Accessed February 25, 2005.
32. Keresztes RS, Socinski M, Bonomi P, et al. Phase II randomized trial of irinotecan/docetaxel (ID) or irinotecan/gemcitabine (IG) with or without celecoxib (CBX) in 2nd-line treatment of non-small-cell lung cancer (NSCLC) [abstract]. J Clin Oncol 2004;22(Suppl 14S):A7137.
33. Lilenbaum R, Socinski M, Altorki N, et al. Phase II randomized trial of irinotecan/docetaxel or irinotecan/gemcitabine with or without celecoxib in 2nd-line treatment of non-small-cell lung cancer [abstract]. Lung Cancer. 2005;49(Suppl 2):S89.
34. Simon R, Wittes RE, Ellenberg SS. Randomized phase II clinical trials. Cancer Treatment Reports. 1985;69:1375-1381.
35. Georgoulias V, Kouroussis C, Agelidou A, et al. Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study. Br J Cancer. 2004;91:482-488.
36. Georgoulias V, Agelidou A, Syrigos K, et al. Second-line treatment with irinotecan plus cisplatin vs cisplatin of patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine: a multicenter randomised phase II study. Br J Cancer. 2005;93:763-769.
37. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 2005;366:1527-1537.
38. Shepherd FA, Rodrigues PJ, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123-132.
39. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 2003;290:2149-2158.
40. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer.[see comment]. J Clin Oncol. 2003;21:2237-46.
41. Cufer T, Vrdoljak E, on behalf of the SIGN study group. Results from a Phase II, open-label, randomized study (SIGN) comparing gefitinib with docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer [abstract]. J Clin Oncol 2005;23(Suppl 16S):A7035.
42. Cufer T, Vrdoljak E. on behalf of the SIGN study group. Results from a Phase II, open-label, randomized study (SIGN) comparing gefitinib with docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer [Slide presentation online]. Available at: http://www.asco.org/ac/1,1003,_12-002511-00_18-0034-00_19-003137,00.asp. Accessed June 28, 2005.
43. Shepherd FA, Pereira J, Ciuleanu T, et al. A randomized placebo controlled study of erlotinib (OSI-774, Tarceva™) versus placebo in patients with incurable non-small cell lung cancer who have failed standard therapy for advanced or metastatic disease. Clinical predictors or response and prognostic markers of survival. [Slide presentation online]. Available at: http://www.asco.org/ac/1,1003,_12-002511-00_18-0026-00_19-0011620-00_21-008, 00.asp. Accessed July 21, 2004.
44. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med. 2005;353:133-144.
45. Bezjak A, Shepherd F, Tu D, et al. Symptom response in non-small cell lung cancer (NSCLC) patients (pts) treated with erlotinib: Quality of life analysis of the NCIC CTG BR. 21 trial [abstract]. J Clin Oncol 2005;23 (16S):A7018.
46. Cella D, Herbst RS, Lynch TJ, et al. Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial. J Clin Oncol. 2005;23:2946-2954.
47. Lynch T, Bell D, Haber D, et al. Correlation of molecular markers including mutations with clinical outcomes in advanced non small cell lung cancer (NSCLC) patients (pts) treated with gefitinib, chemotherapy or chemotherapy and gefitinib in IDEAL and INTACT clinical trials [abstract]. J Clin Oncol. 2005;25(Suppl 16S):A7006.
48. von Pawel J, Shepherd F, Gatzmeier U, et al. Randomized phase 2 study of the oral histone deacetylase inhibitor CI-994 plus gemcitabine (Gem) vs placebo (PBO) plus Gem in second-line nonsmall cell lung cancer (NSCLC) [abstract]. Proc Am Soc Clin Oncol 2002;21:Abstract 1239.
49. Copley-Merriman K, von Pawel J, Shepherd F, et al. Randomized phase 2 study of the oral histone deacetylase inhibitor CI-994 plus gemcitabine vs placebo plus gemcitabine in second-line nonsmall cell lung cancer (NSCLC): health-related quality of life results [abstract]. Proc Am Soc Clin Oncol. 2002;21:Abstract 1294.
50. Raghunadharao D, Koralewski P, Serwatowski P, et al. A randomized phase II study of pivanex and docetaxel compared to docetaxel monotherapy in patients with previously treated advanced NSCLC [abstract]. Lung Cancer. 2005;49(Suppl 2):S265.
51. Fanucchi M, Fosella F, Fidias P, et al. Bortezomib ± docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): a phase 2 study [abstract]. J Clin Oncol. 2005;23(Suppl 16S):A7034.
52. Fanucchi M, Fosella F, Fidias P, et al. Bortezomib ± docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): a phase 2 study [Slide presentation online]. Available at: http://www.asco.org/ ac/1,1003,_12-002511-00_18-0034-00_19-003581,00.asp. Accessed June 28, 2005.
53. Vansteenkiste JF, Breton JL, Sandler A, et al. A Randomized phase II study of epothilone analog BMS-247550 in patients (pts) with non-small cell lung cancer (NSCLC) who have failed first-line platinum-based chemotherapy [abstract]. Proc Am Soc Clin Oncol. 2003;22:626. Abstract 2519.
54. Vansteenkiste JF, Breton JL, Sandler A, et al. A randomized phase II study of epothilone analog BMS-247550 in patients (pts) with non-small cell lung cancer (NSCLC) who have failed first-line platinum-based chemotherapy [ASCO slide presentation online]. Available at: http://www.asco.org/ac/1,1003,_12- 002511-00_18-0023-00_19-003319,00. asp. Accessed February 14, 2005.
55. McAlister FA, Sackett DL. Active-control equivalence trials and antihypertensive agents. Am J Med. 2001;111:553-558.
56. Ross HJ, Rudin CM, Hart LL, et al. Randomized phase II study of SGN-15 (CBR96-doxorubicin immunoconjugate) with docetaxel in patients with advanced or metastatic non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol ASCO Annu Meeting Proc. (Post-Meeting Edition) 2004;22 (Jul 15 Suppl 14S):A7039.
57. Herbst RS, Maddox AM, Small EJ, et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: Results of a phase I trial. J Clin Oncol. 2002;20:3815-3825.
58. Hidalgo M, Siu LL, Nemunaitis J, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol. 2001;19:3267-3279.